2Christopher G.Azzoli,Sherman Baker,Sarah Temin,et al.American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer[J].J Clin Oncol.2009,27 (36):6251-6266.
6Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment [ J ]. Support Care Cancer,2002,10 (2) :88-95.
7Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induce nausea and vomiting: Current and new standards in the antiemetic prophylaxis and treatment [ J ]. Eur J Cancer, 2005,41 ( 2 ) : 199-205.
8Tan M. Granisetron : new insights into its use for the treatment of chemotherapy-induced nausea and vomiting[J ]. Expert Opin Pharmacother,2003,4(9) :1563-1571.
9Hesketh P J, Grunberg SM, Gralla RJ, et al. The Oral Neurokinin-1 Antagonist Aprepitam for the Prevention of Chemotherapy-Induced Nausea and Vomiting:A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin-The Aprepitant Protocol 052 Study Group[ J]. J Clin Oncol,2003,21:4112-4119.
10Poli BS,Rodrigues PJ,Carides AD,et al. Addition of the neu- rokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo- controlled trial in Latin America[ J]. Cancer,2003,97 (12) : 3090-3098.
